Abbvie’s JAK inhibitor Rinvoq (upadacitinib) beat out placebo at week 24 in posthoc analyses of two Phase 3 studies focused on people with active psoriatic arthritis. In particular, the drug led to a superior clinical response related to axial involvement, which occurs in a substantial portion of people with psoriatic arthritis.
Sharing the data at the American College of Rheumatology (ACR) Convergence 2021 conference, AbbVie says the data underscore the drug’s potential for many people with psoriatic arthritis. “These data further add to the body of evidence that support the potential of upadacitinib to be an important treatment option that helps reduce the impact of the many disease manifestations of psoriatic arthritis,” said Dr. Thomas Hudson, senior vice president, research and development, chief scientific officer of AbbVie, in a press release.
Last year, Rinvoq generated $731 million in net revenues globally.
FDA approved Rinvoq in 2019 to treat moderate-to-severe rheumatoid arthritis.
Earlier this year, the company announced that the FDA would not meet the PDUFA action dates for the supplemental New Drug Applications for Rinvoq to treat adults with active psoriatic arthritis and adults with active ankylosing spondylitis.
The recent data related to Rinvoq are from the SELECT-PsA 1 and SELECT-PsA 2 studies.